Nuvation Bio Inc (NYSE: NUVB) has experienced a rise in its stock price by 10.07 compared to its previous closing price of 2.68. However, the company has seen a gain of 10.07% in its stock price over the last five trading days. Business Wire reported 2024-04-24 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncolo.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
NUVB has 36-month beta value of 1.45. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 134.69M, and currently, short sellers hold a 2.37% ratio of that float. The average trading volume of NUVB on April 30, 2024 was 1.33M shares.
NUVB’s Market Performance
The stock of Nuvation Bio Inc (NUVB) has seen a 10.07% increase in the past week, with a -18.96% drop in the past month, and a 69.54% gain in the past quarter. The volatility ratio for the week is 5.81%, and the volatility levels for the past 30 days are at 8.02% for NUVB. The simple moving average for the past 20 days is -1.75% for NUVB’s stock, with a 68.05% simple moving average for the past 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at 15.77% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.08% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 5.81%, as shares sank -20.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +64.80% upper at present.
During the last 5 trading sessions, NUVB rose by +10.07%, which changed the moving average for the period of 200-days by +72.51% in comparison to the 20-day moving average, which settled at $2.97. In addition, Nuvation Bio Inc saw 95.36% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -378.11 for the present operating margin
- 0.29 for the gross margin
The net margin for Nuvation Bio Inc stands at -268.97. The total capital return value is set at -0.16. Equity return is now at value -12.03, with -11.72 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.97.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 2290.13. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 44.11.
Conclusion
To put it simply, Nuvation Bio Inc (NUVB) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
